Article -> Article Details
Title | Myasthenia Gravis Disease Market Share, Growth, Opportunities and forecast |
---|---|
Category | Fitness Health --> Health Articles |
Meta Keywords | Myasthenia Gravis Disease Market, Myasthenia Gravis Disease Market Size, Myasthenia Gravis Disease Market Industry, Global Myasthenia Gravis Disease Market, |
Owner | Vaibhav |
Description | |
Myasthenia Gravis Disease Market The surging
cases of neuromuscular disorders are estimated to favor the market growth
globally. Myasthenia gravis is referred to as a neuromuscular disorder which
results in the skeletal muscles to weaken. The Myasthenia
Gravis Disease Market Share is projected to reach USD 1.9 Billion by 2030 at 7.70% CAGR during the
forecast period 2022-2030. The disease
generally occurs due to the impairment of communication between the nerve cells
and the muscles and causes difficulty in the relaxation and contraction of
muscles. The antibodies present in the body destroy the receptor for
acetylcholine at the neuromuscular joint which prevents the muscles from
contracting and performing its normal function. Major Key
Players: Leading Key Market Players
are Fresenius Kabi, GSK plc, AbbVie Inc., Biogen Inc., Bristol-Myers Squibb
Co., F. Hoffman-La Roche Ltd., Cipla, RPG Life Sciences, Teva Pharmaceutical
Industries Ltd., Apotex Corporation, Novartis, Piramal Healthcare, Sun
Pharmaceuticals Industries Ltd., and Valeant. Segment Analysis The global Myasthenia Gravis Disease Market Outlook
on the basis of diagnosis, treatment, and end-user. On the basis of diagnosis, the global myasthenia
gravis disease market can be segmented into imaging, blood tests,
electrodiagnostic, edrophonium tests, pulmonary function tests, and others. The
imaging segment is classified into X-ray, computed tomography (CT), magnetic
resonance imaging (MRI), and others. On the basis of treatment, the global myasthenia
gravis disease market can be segmented into medication, surgery, autologous
hematopoietic stem cell transplantation (HSCT), plasmapheresis and intravenous
immunoglobulin, and others. By medication, the market is divided into
acetylcholinesterase inhibitors, immunosuppressants, steroids, and others. The
acetylcholinesterase inhibitors segment is further classified into atropine,
neostigmine, pyridostigmine, and others. Immunosuppressant drugs are further
divided into azathioprine, mycophenolate mofetil, tacrolimus, and rituximab.
The steroids segment is further divided into prednisone and others. Surgery is
divided into thymectomy and others. On the basis of end user, the global myasthenia
gravis disease market is segmented into hospitals, clinics, academic research
institutes, and others. Regional Analysis The global myasthenia gravis
disease market is expected to be dominated by North America over the forecast
period, with the Americas segment holding the dominant share in the market. The
Americas market for myasthenia gravis disease is mainly driven by the growing
awareness about the disease, as neurological diseases have been studied in
detail in the region and awareness about this kind of disease is significantly
high in the region. The growing demand for effective medications for
neuromuscular diseases such as myasthenia gravis is likely to drive the drug
development scenario in the Americas region over the forecast period, leading
to steady growth of the myasthenia gravis disease market. Europe holds the second largest
share in the global myasthenia gravis disease market and is likely to remain a
leading contender in the global market over the forecast period due to the
growing awareness about neuromuscular conditions. Myasthenia gravis holds a
significant position in the Europe market, as the disease can cause a
significant burden on national healthcare systems. The increasing financial
burden of myasthenia gravis disease is likely to drive the myasthenia gravis
disease market in Europe over the forecast period. Asia Pacific is likely to be a
major regional market for myasthenia gravis disease over the forecast period
due to the growing awareness about the disease and the increasing desire to
eliminate the disease from urban populations in growing economies such as
China, India, Japan, and South Korea. Increasing healthcare expenditure in the
region is likely to be a major driver for the myasthenia gravis disease market
over the forecast period. Rising awareness about neuromuscular diseases is
likely to be a key driver for the myasthenia gravis disease market in Asia
Pacific over the forecast period. About Market Research
Future At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services. MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by products, services, technologies, applications, end
users, and market players for global, regional, and country level market
segments, enable our clients to see more, know more, and do more, which help to
answer all their most important questions. In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members. Contact us: Market Research Future
(part of Wantstats Research and Media Private Limited), 99 Hudson Street, 5Th Floor, New York, New York 10013 United States of America +1 646 845 9312 |